BJCM
Blue Jay Capital Management Portfolio holdings
AUM
$147M
1-Year Return
64.18%
This Quarter Return
+15.38%
1 Year Return
+64.18%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$203M
AUM Growth
+$37.7M
(+23%)
Cap. Flow
+$22.8M
Cap. Flow
% of AUM
11.23%
Top 10 Holdings %
Top 10 Hldgs %
53.62%
Holding
27
New
12
Increased
1
Reduced
8
Closed
6
Top Buys
| 1 |
Biogen
BIIB
|
+$12.7M |
| 2 |
Globus Medical
GMED
|
+$11.8M |
| 3 |
WMGI
Wright Medical Group Inc
WMGI
|
+$9.53M |
| 4 |
ABMD
Abiomed Inc
ABMD
|
+$9.39M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
+$9.37M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
+$11M |
| 2 |
Hologic
HOLX
|
+$11M |
| 3 |
Labcorp
LH
|
+$10.9M |
| 4 |
Boston Scientific
BSX
|
+$10.8M |
| 5 |
SHPG
Shire pic
SHPG
|
+$10.6M |
Sector Composition
| 1 | Healthcare | 78.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TSRO
1
DELISTED
TESARO, Inc.
TSRO
| $13M | 6.4% |
84,649
-5,046
| -6% | -$776K |
|
|
2
Biogen
BIIB
$21.1B
| $12.7M | 6.23% |
+46,320
| New | +$12.7M |
|
|
3
Globus Medical
GMED
$7.9B
| $11.8M | 5.82% |
+400,000
| New | +$11.8M |
|
4
Ironwood Pharmaceuticals
IRWD
$208M
| $11.5M | 5.66% |
805,950
-116,259
| -13% | -$1.66M |
|
|
QGENF
5
DELISTED
QIAGEN NV
QGENF
| $11.3M | 5.55% |
390,000
-48,572
| -11% | -$1.41M |
|
6
Bristol-Myers Squibb
BMY
$94.6B
| $10.9M | 5.35% |
200,000
+30,000
| +18% | +$1.63M |
|
|
CLVS
7
DELISTED
Clovis Oncology, Inc.
CLVS
| $9.55M | 4.7% |
150,000
-148,982
| -50% | -$9.49M |
|
|
WMGI
8
DELISTED
Wright Medical Group Inc
WMGI
| $9.53M | 4.68% |
+306,165
| New | +$9.53M |
|
|
ABMD
9
DELISTED
Abiomed Inc
ABMD
| $9.39M | 4.62% |
+75,000
| New | +$9.39M |
|
|
NVRO
10
DELISTED
NEVRO CORP.
NVRO
| $9.37M | 4.61% |
+100,000
| New | +$9.37M |
|
11
Incyte
INCY
$16.2B
| $9.31M | 4.58% |
69,678
-39,693
| -36% | -$5.31M |
|
|
BCR
12
DELISTED
CR Bard Inc.
BCR
| $9.3M | 4.57% |
37,419
-14,958
| -29% | -$3.72M |
|
13
BioMarin Pharmaceuticals
BMRN
$10.3B
| $9.22M | 4.53% |
+105,000
| New | +$9.22M |
|
|
NUVA
14
DELISTED
NuVasive, Inc.
NUVA
| $9.21M | 4.53% |
+123,317
| New | +$9.21M |
|
|
PRAH
15
DELISTED
PRA Health Sciences, Inc.
PRAH
| $9.13M | 4.49% |
+140,000
| New | +$9.13M |
|
|
CELG
16
DELISTED
Celgene Corp
CELG
| $9.07M | 4.46% |
+72,902
| New | +$9.07M |
|
17
Vertex Pharmaceuticals
VRTX
$102B
| $8.77M | 4.31% |
+80,161
| New | +$8.77M |
|
18
Edwards Lifesciences
EW
$45.8B
| $8.47M | 4.16% |
270,000
-39,087
| -13% | -$1.23M |
|
|
MDRX
19
DELISTED
Veradigm Inc. Common Stock
MDRX
| $7.48M | 3.68% |
+590,000
| New | +$7.48M |
|
|
AKRX
20
DELISTED
Akorn, Inc.
AKRX
| $7.22M | 3.55% |
+300,000
| New | +$7.22M |
|
|
DERM
21
DELISTED
Dermira, Inc.
DERM
| $7.16M | 3.52% |
210,000
-140,000
| -40% | -$4.78M |
|
|
22
Boston Scientific
BSX
$152B
| – | – |
-498,303
| Closed | -$10.8M |
|
|
23
Hologic
HOLX
$14.3B
| – | – |
-273,478
| Closed | -$11M |
|
|
24
Labcorp
LH
$23B
| – | – |
-98,940
| Closed | -$10.9M |
|
25
ResMed
RMD
$39.8B
| – | – |
-145,000
| Closed | -$9M |
|